The research team assessed whether adjuvant chemotherapy is associated with long-term survival benefit in resected gastric cancer. They also compared this with other prognostic factors.
The team's findings are published in the April issue of the Journal of Surgical Oncology.
The team included 314 consecutive patients with totally resected gastric adenocarcinoma in the study.
|Survival benefit in patients who had received adjuvant chemotherapy.|
|Journal of Surgical Oncology|
In 151 patients no adjuvant therapy was given.
However, 163 patients received 4 courses of adjuvant chemotherapy. Of these, 109 received mitomycin (MMC) alone, and 54 received (MMC) plus Tegafur (TG).
The team performed both univariate and multivariate survival analyses.
The researchers identified a survival benefit in patients who had received adjuvant chemotherapy, compared with the controls. They found that 52% versus 30% were alive at the end of the study (relative risk 0.46)
They also identified a survival benefit in women (52% versus 35%, RR 0.83).
Increment of staging also influenced survival (IB, II, IIIA, or IIIB had 80%, 56%, 24% and 13% survival, respectively, RR 1.83).
Better prognosis of node-negative patients was observed only in univariate analysis.
Dr Juan Grau's team concluded, "After curative surgery, adjuvant chemotherapy with mitomycin C…improved the long-term cure rate over no postoperative chemotherapy in locally advanced gastric cancer patients".
"This benefit was not influenced by other prognostic factors."